About MyOme
MyOme is a Healthcare company based in San Carlos (United States) founded in 2017 by Kate Im, Akash Kumar, and Matthew Rabinowitz. Provider of a platform for gene analysis to determine genetic diseases and drug response. MyOme has raised $23 million across 1 funding round from investors including Healthcare Ventures. MyOme offers products and services including Proactive Health Tests, Diagnostic Tests, and Integrated Polygenic Risk Score. Its focus areas include Life Sciences, Genomics, Applied Genomics and Consumer Genomics. Its legal entity is MyCarrier TMS. Its competitors include InformedDNA, Arivale and GB HealthWatch; 3 of its 3 listed competitors have raised funding.
Company details
MyOme was founded in 2017 and is headquartered in San Carlos, United States. A platform for whole-genome sequencing is offered in the genomics sector to calculate genome risk scores. These scores are used to evaluate risks for common conditions such as heart disease and complex rare disorders influenced by multiple genetic elements. Drug response insights are also generated. Additionally, whole-genome analysis services are available for embryo selection during IVF procedures.
- Total Equity Funding$23M (USD)
in 1 rounds
- Latest Funding Round$23M (USD), Series B
Jun 2022
- Investors
Products & Services of MyOme
MyOme offers a comprehensive portfolio of products and services, including Proactive Health Tests, Diagnostic Tests, and Integrated Polygenic Risk Score.
Assesses personal health risks for prevention and treatment decisions.
Provides testing for rare diseases and exome analysis.
Combines factors for personalized risk assessments across ancestries.
Funding Insights of MyOme
MyOme has successfully raised a total of $23M through 1 strategic funding round. The most recent funding activity was a Series B round of $23 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23M
- Total Rounds 1
- Last Round Series B — $23M
- First Round $23M
(Jun 2022)
- Investors Count 1
All 1 funding rounds of MyOme with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $23M | Series B | – | Healthcare Ventures | – |
1 investors in total: 1 institutional.
Investors in MyOme
MyOme has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Healthcare Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| hcven.com |
Investor details for MyOme
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MyOme
24 people are tracked at MyOme (11 in leadership, 5 in board & advisors, 8 in team).
| Name | Role | Group |
|---|---|---|
Kate Im | Co-Founder & Head of Research | Leadership |
Akash Kumar | Co-Founder & Chief Medical & Scientific Officer | Leadership |
Matthew Rabinowitz | Co-Founder & Chairman | Leadership |
Premal Shah | CEO | Leadership |
Yasser M Ads | Chief Business Officer | Leadership |
Adam Lavertu | Chief Technology Officer | Leadership |
Donna Hongo | Head of Quality & Regulatory | Leadership |
Darisha Jiandani | Head Of Marketing | Leadership |
Matt Curley | Head Of Commercial Operations | Leadership |
Joseph Solomon | Director Of Engineering - Integrations And Portals | Leadership |
Lindsay Meyers | Head Of Clinical Affairs | Leadership |
Jonathan Sheena | Board Member & Advisor | Board & advisors |
Jacob Kitzman | Advisor | Board & advisors |
Russ B. Altman | Advisor | Board & advisors |
Stephen Montgomery | Advisor | Board & advisors |
Trevor Hastie | Advisor | Board & advisors |
Taryn Serman | Senior Marketing Manager | Team |
Dylan Reinhardt | Software Engineer | Team |
Michelle Vier | Corporate Operations Manager | Team |
David H. Ledbetter | Senior Consultant | Team |
4 more people are available in the full profile.
Complete people profiles for MyOme
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MyOme
2 dated milestones of MyOme across 5 years, from founding to its latest funding, stage changes and deals.
- Founded MyOme is founded.
- Funding First funding round of $23.0M.
Competitors of MyOme
MyOme has 3 listed competitors in our database, 3 of them funded. They include InformedDNA, Arivale and GB HealthWatch.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| informeddna.com | 2007 | St Petersburg, United States | $19.22M | Network of genetics experts provided to assist patients and providers. | ||
| arivale.com | 2014 | Seattle, United States | $49.6M | Provider of direct-to-consumer genetic testing. | ||
| gbhealthwatch.com | 2012 | San Diego, United States | $9.78M | Personalized nutrition plans are offered via an online health platform. |
Detailed competitors of MyOme
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MyOme
The website of MyOme (myome.com) receives about 5.3K visits a month.
- Monthly visits5.3K
▼ 37.2% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as MyOme (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Myome
Complete news archive for MyOme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MyOme
MyOme was founded in 2017 and raised its 1st funding round 5 years after it was founded.
MyOme is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
MyOme is a funded company, having raised a total of $23M across 1 funding round to date. The company's 1st funding round was a Series B of $23M, raised on Jun 2022.
MyOme was founded in 2017 and is headquartered in San Carlos, United States. A platform for whole-genome sequencing is offered in the genomics sector to calculate genome risk scores. These scores are used to evaluate risks for common conditions such as heart disease and complex rare disorders influenced by multiple genetic elements. Drug response insights are also generated. Additionally, whole-genome analysis services are available for embryo selection during IVF procedures.
MyOme's top competitors include InformedDNA, Arivale and GB HealthWatch.
MyOme offers Proactive Health Tests, Diagnostic Tests, and Integrated Polygenic Risk Score.
MyOme has 1 investor. Key investors include Healthcare Ventures.
MyOme operates through Mycarrier Tms.